Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
IART Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.81 - $45.41
Previous CloseN/A
Volume73.30K
Average Volume (3M)549.62K
Market Cap
$1.80B
Enterprise Value$3.10B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Feb 25, 2025EPS Estimate
0.85Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,163,520
10 Day Avg. Volume493,072
30 Day Avg. Volume549,615
Standard Deviation0.11
R-Squared0.33
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.15
Price to Cash Flow (P/CF)20.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda13.27
Forecast
1Y Price Target
$20.50Price Target Upside-9.57% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering4
---
Integra Lifesciences News
PremiumCompany Announcements
Integra Lifesciences Implements New Severance Program for Executives
PremiumCompany Announcements
Integra LifeSciences Announces Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSecond-quarter sales exceeded expectations, coming in ahead of guidance and beating consensus estimates.
Management And LeadershipA new CEO and focus on QMS systems could drive growth acceleration in 2025 off an easy comp.
ValuationShares are starting to appeal to deep value investors, indicating interest in a turnaround opportunity.
Bears Say
Guidance And ForecastsStreet estimates for FY25 appear to be too high, suggesting a potential misalignment with management's preliminary guidance.
Regulatory IssuesA Warning Letter from the FDA was issued relating to quality system issues at several IART facilities.
Supply ChainPotential remains for further supply disruptions, and near-term pressure on shares from tax-loss selling into year-end is expected.
---
Ownership Overview
3.19% Insiders
31.05% Mutual Funds
20.01% Other Institutional Investors
17.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $16.80 and its highest was $45.41 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is $1.80B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Feb 25, 2025 which is in 4 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Nov 04, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Overvalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. pays a Notavailable dividend of $3.184 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences Holdings Corp. dividends here
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.85.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,163,520 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.41 in its last earnings report, beating expectations of $0.39. Following the earnings report the stock price went up 25.104%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in IART
---
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$20.50 (-9.57% Downside)
$20.50 (-9.57% Downside)
Blogger Sentiment
Bullish
IART Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 521.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $141.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.66%
12-Months-Change
Fundamentals
Return on Equity
-0.42%
Trailing 12-Months
Asset Growth
8.73%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a mix of positive developments, such as a promising leadership transition and strong demand in key segments, against significant challenges like revenue decline, supply chain issues, and reduced margins. The Acclarent acquisition's success was a bright spot, but overall, the company faces ongoing operational difficulties and compliance hurdles.Read More>---
IART Stock 12 Month Forecast
Average Price Target
$20.50
▼(-9.57% Downside)
Technical Analysis
Best Analysts Covering IART
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+11.83%
reiterated a sell rating 2 months ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +11.83% per trade.
---